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Regulation of Electronic Cigarettes 
in the United States
Azim Chowdhury
Abstract
In the United States, the manufacture, distribution and marketing of tobacco 
products is regulated by the US Food and Drug Administration (FDA), pursuant 
to authority extended to the agency in 2009 with the enactment of the Family 
Smoking Prevention and Tobacco Control Act (Tobacco Control Act). While that 
law initially gave FDA authority over certain categories of tobacco products (e.g., 
cigarettes, smokeless tobacco and roll-your-own tobacco), in August 2016, FDA’s 
“Deeming Rule” extended that authority to all products that are made from or 
contain tobacco-derived substances, such as nicotine. Now, products such as cigars, 
pipe tobacco, shisha/hookah and electronic cigarettes (e-cigarettes) are subject 
to the Tobacco Control Act and FDA’s authority. But regulators have struggled to 
keep up with the evolving technology and are still grappling with the public health 
consequences—both pro and con—and continue to adopt policies and regulations 
to address new issues that emerge (i.e., underage use and flavors).
Keywords: FDA, e-cigarette, tobacco, nicotine, Deeming, Tobacco Control Act, 
flavors, PMTA, premarket review, continuum of risk
1. Introduction
The emergence of less risky novel or “next generation” tobacco products such 
as e-cigarettes and heat-not-burn devices coincided with new regulatory authority 
provided to the US Food and Drug Administration (FDA), the health agency in 
charge of regulating the safety of consumer products such as food, drugs, medical 
devices, and cosmetics, under the Family Smoking Prevention and Tobacco Control 
Act (Tobacco Control Act), which amended the existing Food, Drug, and Cosmetic 
Act (FDCA or Act). Pursuant to this new law, FDA now has the authority to regulate 
the manufacture, distribution, and marketing of tobacco products in the United 
States [1].
When it was signed into law in June 2009, the Tobacco Control Act provided 
FDA with immediate authority only over four categories of tobacco products, that 
is, cigarettes, cigarette tobacco, smokeless tobacco, and roll-your-own tobacco. 
Subsequently, in 2016, FDA finalized its “Deeming Rule,” 81 Fed. Reg. 28974 (May 
10, 2016), which deemed all products that meet the tobacco product definition 
(including, but not limited to, e-cigarettes, heat-not-burn, cigars, hookah/water-
pipe, and pipe tobacco products) to be subject to its Tobacco Control Act authority. 
Now, newly deemed products are subject to a host of federal requirements includ-
ing, among other things, premarket authorization for new products, ingredient 
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reporting, manufacturing establishment registration, harmful constituent testing, 
and sales and marketing restrictions.
Rising underage use of e-cigarettes has underscored the need for increased FDA 
enforcement of the Tobacco Control Act requirements, and has resulted in new 
policies aimed at restricted youth access to flavored e-cigarettes. This paper pro-
vides a comprehensive review of the regulatory requirements applicable to manu-
facturers and addresses how FDA’s most recent policy announcements could impact 
the industry moving forward.
2. Overview of major Tobacco Control Act requirements
The Tobacco Control Act requires tobacco product manufacturers to, among 
other things, register their US manufacturing establishments with FDA, submit a list 
of US manufactured products, report the ingredients used in their products, submit 
certain health documents in their possession, test their products for specific harmful 
and potentially harmful constituents (HPHCs), include nicotine addiction warnings 
and certain other information on their labels and, most critically, obtain premarket 
authorization for any new products. Manufacturers are also subject to the adultera-
tion and misbranding provision of the Act and are prohibited from making modified 
risk claims about their products without specific FDA authorization.
2.1 Marketing and sales restrictions
With respect to the sales and marketing of deemed products, FDA’s Deeming 
Rule bans claims of reduced or “modified” risk and free samples to consumers, sets 
the minimum purchase age to 18 years, requires photo-ID verification at the point-
of-sale, restricts vending machine sales of covered tobacco products to adult-only 
facilities, and requires nicotine addiction warnings on labels and advertising [2]. 
Furthermore, it is illegal to market or distribute any tobacco product whose packag-
ing or labeling is misbranded under Section 903 of the FDCA, or deceptive and 
misleading under Section 5 of the Federal Trade Commission (FTC) Act.
2.2 US establishment registration and product listing
Section 905(b) of the Tobacco Control Act requires every person who owns or 
operates any establishment in the United States that manufactures, prepares, com-
pounds, or processes finished tobacco products to register such establishment with 
FDA and submit a product list, which must be updated biannually (every December 
31 and June 30) [3]. Foreign establishments are not presently required to register 
with FDA, but the agency has the authority to promulgate a regulation requiring 
them to do so. Here, the phrase “manufacture, preparation, compounding, or 
processing” includes repackaging or otherwise changing the container, wrapper, or 
labeling of any tobacco product package in furtherance of the distribution of the 
tobacco product. US importers of tobacco products do not register with FDA unless 
they are also engaged in a manufacturing activity in the United States.
As noted, at the time of registration, registrants must submit to FDA a detailed 
list of all products that are being manufactured, prepared, compounded, or pro-
cessed for commercial distribution in the United States, along with all labeling, and 
a representative sampling of advertisements. The term “commercial distribution” 
includes any distribution of a tobacco product to consumers or to another person 
for further manufacturing through sale or otherwise [4]. Registrants must also file a 
biannual report of certain changes to their product lists [5].
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Registered establishments are subject to FDA inspection every 2 years [6]. FDA 
may inspect factories, warehouses, and other establishments in which tobacco 
products are manufactured, processed, packed, or held, as well as any vehicle being 
used to transport or hold such products [7].
2.3 Ingredient reporting
Section 904(a)(1)-(2) of the Tobacco Control Act requires that a manufacturer 
or importer submit a listing of all ingredients, as well as a description of the con-
tent, delivery, and form of nicotine in each tobacco product [8]. “Ingredients” here 
includes “tobacco, substances, compounds, and additives” [9]—that are added to 
any component or part of the products (e.g., to the tobacco, paper, filter, or other 
part). Products must be identified by brand and sub-brand and the ingredients 
by quantity in each brand and sub-brand. Manufacturers and importers are also 
required to submit information whenever any additive, or the quantity of any addi-
tive, is changed [10]. This requirement applies to all manufacturers no matter where 
they are located.
However, on April 13, 2018, FDA published a Revised Guidance for Industry 
which clarified that, at this time, FDA is effectively exempting e-cigarette device 
and hardware component/part manufacturers from the ingredient listing require-
ment [11]. Rather, FDA only intends to enforce the Section 904 ingredient listing 
requirement with respect to those tobacco products that are (1) made or derived 
from tobacco, or (2) made with consumable ingredients that are burned, aerosolized 
or ingested when the tobacco product is being used. Specifically, for e-cigarettes, 
FDA is now only seeking ingredient information on e-liquids, and not any hardware 
or components/parts such as:
• Electrical components including, but not limited to, batteries, charging systems, 
circuit boards, wiring, and connectors
• System software
• Digital display, lights, and buttons to adjust settings
• Connection adapters
• Cartomizers
• Coils
• Wicks
• Tanks
• Mouthpieces
2.4 Reporting health documents
Section 904 obligates tobacco product manufacturers and importers to submit 
certain health information to FDA. Specifically, manufacturers and importers are 
also required to submit all documents relating to the health, toxicological, behav-
ioral, or physiologic effects of current or future tobacco products, constituents, 
ingredients, components, and additives (collectively, “Health Documents”). The 
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term “documents” is defined broadly and includes “writings, drawings, graphs, 
charts, photographs, sound recordings, images, and other data or data compila-
tions—stored in any medium from which information can be obtained either 
directly or, if necessary, after translation by the responding party into a reasonably 
usable form.” At this time, however, FDA is only requesting health documents 
developed between June 23, 2009 and December 31, 2009. Companies that may 
not have been in business, or who were not producing health documents on their 
tobacco products at that time, are still required to notify FDA that they do not have 
any relevant health documents in their possession [12].
2.5 Harmful constituent testing
Section 904(a)(3) requires manufacturers and importers to report quantities of 
HPHCs found in tobacco products or tobacco smoke by brand and sub-brand. Out 
of more than 7000 such constituents, FDA has established a list of 93 HPHCs that 
tobacco companies will ultimately be required to report for every regulated tobacco 
product sold in the USA [13]. However, in recognition of current testing limitations 
for certain constituents on FDA’s list, FDA has created representative or “abbrevi-
ated” lists of constituents for cigarettes, roll-your-own, and smokeless tobacco for 
which testing methods are well established and widely available [14].
With respect to e-cigarettes, as of the date of this writing, FDA has not provided 
any guidance or initiated rulemaking, so it is unclear whether HPHCs will need to 
be tested in the e-liquids themselves or in the vapor/aerosol formed when used in a 
device. In August 2016 FDA published a revised guidance document expanding the 
definition of HPHC to specifically include substances in the vapor (aerosol) pro-
duced by e-cigarettes. As defined by FDA in the guidance, an HPHC now includes 
any chemical or chemical compound in a tobacco product or in tobacco smoke that: 
(a) is, or potentially is, inhaled, ingested, or absorbed into the body, including as an 
aerosol (vapor) or any other emission; and (b) causes or has the potential to cause 
direct or indirect harm to users or non-users of tobacco products” [14].
FDA is expected to issue formal guidance and regulations for the testing and 
reporting of HPHCs, ingredients, additives and other constituents pursuant to 
Section 915 [15].
2.6 Label requirements
The Deeming Rule extended a number of labeling requirements to deemed 
tobacco products. Specifically, by August 10, 2018, all deemed tobacco products 
must include the following on the labels of all products marketed in the United 
States:
• The name and place of business of the manufacturer, packer, or distributor;
• An accurate statement of the quantity of the contents in terms of weight, mea-
sure, or numerical count; and
• The statement “Sale only allowed in the United States”.
In addition, all nicotine-containing products must include the following 
warning on their labels “WARNING: This product contains nicotine. Nicotine is 
an addictive chemical” [16]. That warning label must comply with the specific 
requirements set forth in 21 C.F.R. § 1143.3(a). The nicotine addiction warning 
requirement, however, does not apply to products that are not sold with or contain 
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nicotine [17]. Rather, covered tobacco products that do not contain nicotine (i.e., 
zero-nicotine e-cigarettes that contain another tobacco-derived ingredient), must 
include the following statement on their label in lieu of the nicotine addiction 
warning: “This product is made from tobacco.” Manufacturers of such products are 
further required to submit a statement to FDA certifying that the product does not 
contain nicotine.
2.7 Premarket authorization for new tobacco products
The Tobacco Control Act requires that FDA authorize the marketing of any 
new tobacco product through a lengthy and complicated application process. If a 
product was on the market as of February 15, 2007 it is considered “grandfathered” 
and exempt from FDA premarket review. If a tobacco product was introduced (or 
is intended to be introduced) after the February 15, 2007 “grandfather date,” or if it 
was modified in any way after that date, it is a new product. Product modifications 
include, but are not limited to changes to a product’s design, ingredients, com-
ponents, parts, delivery mechanism, type of nicotine, etc. Changes to a product’s 
labeling (including brand name, logos, colors, etc.), however, do not trigger the 
premarket review requirements [18].
The substantial equivalence (SE) report and the premarket tobacco application 
(PMTA) are the primary pathways for new tobacco product. The minor modifica-
tion or SE exemption pathway is another option but only applies to changes in 
additives so is rarely utilized.
If a manufacturer can demonstrate, through the submission of an SE report, 
that its new product is substantially equivalent to a “predicate” product it may 
be authorized for sale. A “predicate” product is either a grandfathered tobacco 
product (that was on the market as of February 15, 2007), or tobacco product 
that, although not itself grandfathered, has been determined to be substantially 
equivalent to another grandfathered product. To demonstrate substantial equiva-
lence, the manufacturer must provide evidence (such as data showing similarities 
in consumer perception, clinical data, abuse liability data, and toxicology) that 
the new product has the same (identical) “characteristics” as the predicate tobacco 
product or, if it has different characteristics, that the new product “does not raise 
different questions of public health.” In other words, FDA may find a new tobacco 
product to be substantially equivalent to the identified predicate if the new charac-
teristics do not create different public health concerns compared to the predicate. 
Public health concerns may include the potential to increase tobacco use initiation 
or decrease cessation.
For a PMTA, on the other hand, a predicate product is not needed. Rather, the 
manufacturer must demonstrate that the new product meets a very high public 
health standard. Specifically, it must be shown that the product, if made available 
in the United States, would be “appropriate for the protection of the public health.” 
This requires assessing the product’s potential impact on the population, including 
its impact on overall tobacco product cessation rates (i.e., the likelihood that people 
will stop using tobacco products), as well as initiation rates (i.e., the likelihood that 
people will start using tobacco products) [19].
To meet this high standard, FDA has recommended PMTAs include detailed 
scientific literature reviews, as well as numerous non-clinical, clinical (i.e., human), 
and long-term studies be performed, including, but not limited to, in-vitro and 
in-vivo (i.e., animal) toxicological studies (e.g., genotoxicity and cytotoxicity), as 
well as clinical and population-level studies to assess consumer perceptions, likeli-
hood of initiation and cessation, product use patterns, abuse liability, and health 
outcomes [19].
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2.7.1 Compliance policy for deemed tobacco products
As noted, in the final Deeming Rule FDA chose not to amend the February 15, 
2007 grandfather date for deemed products, forcing all next generation products to 
go through pre-market authorization (because there are no known grandfathered 
e-cigarettes or heat-not-burn products). Moreover, as a result, the SE Report path-
way (which, as noted above, requires a manufacturer to compare a new product to a 
predicate product) is unavailable, forcing all next generation products to go through 
the much more onerous and expensive PMTA.
FDA instead established a compliance policy that would allow any finished 
deemed tobacco product marketed after the grandfather date and prior to August 
8, 2016 (the rule’s effective date), to remain on the market for 2 years (without 
premarket authorization) until August 8, 2018, at which time PMTAs would need to 
be submitted. Products subject to such PMTAs that are accepted by FDA for review 
would be permitted to remain on the market for an additional year, until August 
8, 2019 (the “sunset period”), at which point they would have to be removed from 
market and wait for FDA authorization (which, of course, is not guaranteed and 
could take years).
Lawsuits were filed challenging FDA’s failure to change the grandfather date 
and the seemingly arbitrary 2-year PMTA compliance policy, and there has been an 
intense lobbying effort to get Congress to change the grandfather date—so far, to no 
avail [20].
However, on July 28, 2017, FDA announced a new “comprehensive regulatory 
plan to shift the trajectory of tobacco-related disease, death” that refocuses the 
agency’s implementation of the Tobacco Control Act and the Deeming Rule [21]. 
While the focus of the announcement was to highlight the agency’s long-term plan 
to potentially reduce nicotine in cigarettes to “non-addictive” levels, the agency 
also discussed the potential harm-reduction benefits of deemed products like 
e-cigarettes, and appeared to recognize that a “continuum of risk” of tobacco and 
nicotine-containing products exists.
In this regard, as part of its comprehensive policy announcement, FDA delayed 
the Deeming Rule’s compliance policy deadlines to submit premarket authorization 
applications” (i.e., PMTAs or SE reports) for newly deemed tobacco products that 
were on the market on August 8, 2016. Under the new timelines, applications for 
previously marketed (but not grandfathered) combustible products, such as cigars, 
pipe tobacco and hookah tobacco, are now due by August 8, 2021, and applications 
for previously marketed non-combustibles, such as e-cigarettes, e-liquids and heat-
not-burn products are due by August 8, 2022. FDA also indicated that it would be 
revising the sunset policy so that existing products under review can remain on the 
market pending review of their applications. New products intended to enter the 
market after August 8, 2016 must still obtain FDA marketing authorization before 
entering the market.
This new compliance policy delaying premarket review provided the industry, 
which was facing a de facto ban in 2018, much needed breathing room on the most 
complicated and expensive regulatory requirement. Critical to ensuring that such 
ban is not simply delayed until 2022 will depend, in part, on whether FDA provides 
more guidance and clarity on the PMTA process and requirements—particularly 
how to satisfy the population-level public health standard.
In addition to extending the premarket review deadlines for deemed products, 
FDA announced that it will publish advance notices of proposed rulemaking 
(ANPRMs) to seek (1) input on the potential public health benefits and possible 
adverse effects of lowering the level of nicotine in cigarettes to non-addictive levels, 
(2) public comments on the role of flavored tobacco products in terms of youth 
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initiation and harm reduction, and (3) scientific data related to the patterns of use 
and resulting public health impacts from premium cigars. FDA also indicated that it 
would develop product standards to address public health risks, such as, e-cigarette 
battery safety issues, and exposure to liquid nicotine by children, as well as examine 
ways to increase access and use of FDA-approved medicinal nicotine products 
intended to help smokers quit [21].
2.8 New FDA policy to address increase in underage e-cigarette use
In April 2018 FDA launched its Youth Tobacco Prevention Plan to address the 
sudden rise in underage use of certain types of e-cigarettes: pre-filled cartridge-
based e-cigarettes sold mainly in convenience stores, gas stations and similar all-age 
retail outlets. FDA stated that between June and September 2018 nearly 1300 retail-
ers across the country had received warning letters and/or monetary penalties for 
selling products to minors [22]. FDA also requested manufacturers of these popular 
cartridge-based e-cigarettes to submit proposals on how they plan to curtail the 
increasing youth-use of their products.
Subsequently, on November 15, 2018, FDA announced a new policy aimed at 
preventing youth access to flavored e-cigarettes [23]. First, FDA announced that 
all flavored e-cigarette products (other than tobacco, mint, and menthol flavors, 
or non-flavored products) will be required to be sold in age-restricted, in-person 
locations, or else potentially be subjected to a revised premarket review compli-
ance policy deadline. This policy revision would apply to all e-cigarettes, including 
e-liquids, cartridge-based systems and cigalikes, in flavors except tobacco, mint, 
and menthol, sold in physical locations where people under age 18 are permitted. 
However, the new restrictions would not apply to e-cigarettes sold exclusively in 
age-restricted locations (e.g., a stand-alone tobacco retailer) that either prevent 
minors (individuals under age 18) from entering the facility at any time, or establish 
a walled-off adult-only section of the facility where flavored e-cigarettes can be 
viewed and purchased by persons 18 and older.
Second, FDA announced that it would seek to curtail the sale of flavored 
e-cigarettes (other than tobacco, mint and menthol) that are sold online without 
“heightened age verification” processes. To advance this goal, FDA plans to identify 
and publish a list of best practices for online retailers [23].
Third, FDA announced that flavored cigars will no longer be subject to the 
extended compliance date for premarket authorization (which currently sets the 
premarket application deadline for cigars on the market on August 8, 2016 to be 
August 8, 2021). However, this policy does not apply to the entire product category, 
as certain flavored cigars are considered “grandfathered” and exempt from premar-
ket review if they were on the market as of February 15, 2007, as discussed above. To 
address this gap in regulatory authority, FDA plans to propose a product standard 
that would ban all flavored cigars [23].
Fourth, FDA announced plans to publish a Proposed Rule in the Federal Register 
that would seek to ban menthol in combustible tobacco products, including ciga-
rettes and cigars [23].
The Commissioner also noted that FDA plans to continue to aggressively pursue 
removing e-cigarettes marketed to children and/or appealing to youth from the 
market. These marketing practices may include “using popular children’s cartoon or 
animated characters” or “names of products favored by kids like brands of candy or 
soda.”
On March 13, 2019 FDA published a new draft guidance document entitled, 
Modifications to Compliance Policy for Certain Deemed Tobacco Products [24]. The draft 
guidance formalizes the November 2018 proposal from FDA discussed above, but 
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makes several changes. More specifically, the draft guidance eliminates the compli-
ance policy for flavored e-cigarettes (other than tobacco, mint, menthol and unfla-
vored products) sold or marketed in a manner that is (a) targeted to minors or likely 
to promote ENDS use by minors, or (b) offered for sale in ways that pose a greater 
risk of minor access. Such products will be subject to immediate enforcement.
In terms of targeting minors, the guidance states that FDA is evaluating how 
companies may utilize social media to market to minors, as well as radio and televi-
sion (which are platforms that are prohibited for cigarette advertising). FDA further 
implied that products with labeling and/or advertising that use “youth appealing 
cartoons as well as the use of minors or people who appear to be minors in multime-
dia advertisements” could be the subject of enforcement. The draft guidance also 
identifies the following circumstances which pose a “greater risks of minor access”:
1. Products sold in locations that minors are able to enter at any time (e.g., the 
entire establishment or an area within the establishment);
2. Products sold through retail establishments and online retail locations that 
have sold to minors—as indicated by FDA’s searchable retailer inspection 
database—after issuance of the final guidance document;
3. Products sold online without a limit on the quantity of product that a customer 
may purchase within a given period of time; or
4. Products sold online without independent, third-party age-and identity-
verification services that compare customer information against third-party 
data sources, such as public records.
The draft guidance also shortens the compliance policy by 1 year for all flavored 
ENDS (other than tobacco, mint, menthol and unflavored products), even if such 
products are marketed responsibly to adults. If the draft guidance is finalized, such 
flavored products on the market on August 8, 2016 will have until August 8, 2021 to 
submit PMTAs (which must be accepted by FDA for substantive review).
Finally, the guidance keeps in place, for the time being, the existing compli-
ance policy for tobacco, mint, menthol and unflavored ENDS on the market as of 
August 8, 2016. Accordingly, these products still have until August 8, 2022 to submit 
premarket applications.
FDA indicated that the reason it is modifying the compliance policy for e-cigarettes 
in the manner described above is (i) “to encourage more prompt filing of premarket 
submissions for certain ENDS products”; (ii) “to focus the Agency’s enforcement 
resources where there is a greater threat to public health”; and (iii) “to balance that pub-
lic health threat against the potential benefit to providing adult smokers noncombus-
tible options to allow them to completely switch from the use of combustible products.”
While it is unclear how FDA will enforce the new compliance policy if it becomes 
effective, the draft guidance expressly places the onus on manufacturers to control 
distribution and sale of their products to retail customers by, among other things, 
“requiring terms, conditions, or controls in their contracts with downstream distrib-
utors (wholesalers, distributors, importers and/or retailers) to prevent youth access.”
3. Conclusion
The e-cigarette industry has grown rapidly in the United States since the products 
were first introduced to the market in 2007. Regulators have struggled to keep up 
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with the evolving technology and are still grappling with the public health conse-
quences—both pro and con. In the USA, the FDA’s new authority over traditional 
tobacco products such as cigarettes was extended to cover e-cigarettes and other novel 
products. Now, newly deemed tobacco products are subject to the Tobacco Control 
Act requirements including, among other things, premarket authorization for new 
products, ingredient reporting, manufacturing establishment registration, harmful 
constituent testing, and sales and marketing restrictions. Regulators also continue to 
adopt policies and regulations to address new issues that emerge (i.e., underage use).
Manufacturers of flavored e-cigarettes should be most concerned with comply-
ing with FDA’s recently revised premarket review compliance policy. In this regard, 
to potentially avoid being subject to immediate enforcement, and to remain eligible 
for the August 8, 2021 PMTA compliance date, manufacturers of flavored e-ciga-
rettes must work with their retailers and distributors to ensure that their products 
are not sold in (1) all-age retailers (i.e., non-adult only facilities such as convenience 
stores and gas stations) that do not have separate walled-off section for flavored 
products, (2) online stores that do not have a limit on bulk purchases or third-party 
age and identity verification services, or (3) brick-and-mortar and online stores 
that have previously been cited for selling products to minors.
Manufacturers must further ensure that their products are not viewed as target-
ing or promoting use to minors. Companies should review their labeling, packaging, 
social media, websites, and advertising/marketing materials with the understand-
ing that FDA could broadly argue that the use of certain flavors, descriptive flavor 
names, packaging and label colors, images of food, fruit, or desert, cartoon images 
or illustrations, playful characters, or young models, among other things, might 
trigger immediate enforcement under the modified compliance policy.
Finally, even if manufacturers can avoid immediate enforcement against their 
flavored e-cigarettes, the August 8, 2021 compliance date is fast approaching. It is 
critical that companies start working to prepare PMTAs sooner rather than later to 
have any chance of meeting that deadline.
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